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KRN 8602 (MX2) is a novel morpholino anthracycline derivative having the chemical structure 30-deamino-30-morpholino-13-deoxo-
10-hydroxycarminomycin hydrochloride. To investigate the mechanisms of resistance to MX2, we established an MX2-resistant
phenotype (K562/MX2) of the human myelogeneous leukaemia cell line (K562/P), by continuously exposing a suspension culture to
increasing concentrations of MX2. K562/MX2 cells were more resistant to MX2 than the parent cells, and also showed cross-
resistance to etoposide and doxorubicin. Topoisomerase (Topo) IIa protein levels in K562/MX2 cells were lower of those in K562/P
cells on immunoblot analysis and decreased expression of Topo IIa mRNA was seen in K562/MX2 cells. Topoisomerase II catalytic
activity was also reduced in the nuclear extracts from K562/MX2 cells when compared with K562/P cells. Aberrant methylated CpG
of Topo IIa gene was observed in K562/MX2 cells when compared with the parent line on methylation-specific restriction enzyme
analysis. To overcome the drug resistance to MX2 and etoposide, we investigated treatment with 5-Aza-20-deoxycytidine (5AZ),
which is a demethylating agent, in K562/MX2 cells. 5-Aza-20-deoxycytidine treatment increased Topo IIa mRNA expression in K562/
MX2 cells, but not in K562/P cells, and increased the cytotoxicity of MX2 and etoposide. Methylated CpG was decreased in K562/
MX2 cells after 5AZ treatment. We concluded that the mechanism of drug resistance to MX2 and etoposide in K562/MX2 cells
might be the combination of decreased expression of Topo IIa gene and increased methylation, and that 5AZ could prove to be a
novel treatment for etoposide-resistant cell lines, such as K562/MX2.
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DNA topoisomerase II (Topo II) is an ATP-dependent enzyme that
makes transient breaks in one segment of double-stranded DNA
and places an intact duplex into the broken DNA before resealing
the break, thus altering DNA topology (Osheroff, 1989; Wang,
1996). The activity of Topo II is important in DNA metabolism, as
well as in forming the nuclear scaffold and nuclear matrix
(Osheroff, 1989; Wang, 1996). The catalytic activity of Topo II in
mammalian cells is mediated by two genetically distinct isoenzyme
forms, designated Topo IIa and Topo IIb, (Mw: 170000 and
180000, respectively) (Wang, 1996). The two isoenzymes appear to
differ in both the nuclear localisation and relative content during
cell cycle transition and cell proliferation (Osheroff, 1989; Wang,
1996).
Topo II has also been identified as the cellular target for many
clinically active antineoplastic agents, including amino acridines,
anthracyclines and epipodophyllotoxins (Zwelling et al, 1989).
These agents act by stabilizing the Topo II enzyme–DNA complex
and the Topo II-associated DNA strand break, which is designated
the cleavable complex (Liu, 1989). The cellular processing of these
complexes results in the generation of DNA double-strand breaks
that eventually leads to cell death (Zwelling et al, 1989). However,
the frequent emergence of resistant cells during treatment with
Topo II-active drugs is a serious problem in cancer therapy
(Zwelling et al, 1989; Harris and Hochhauser, 1992; Zhang et al,
1999).
KRN 8602 (MX2) is a new morpholino anthracycline derivative
with the chemical structure 30-deamino-30-morpholino-13-deoxo-
10-hydroxycarminomycin hydrochloride, and has been shown to
exhibit cytotoxic effects against tumour cells as a Topo II inhibitor
(Watanabe et al, 1988). Owing to its highly lipophilic properties,
MX2 rapidly diffuses through the cell membrane and reaches high
intracellular concentration irrespective of P-glycoprotein expres-
sion levels (Watanabe et al, 1988). MX2 has thus been capable of
antitumour effects superior to those of adriamycin (ADM) against
several murine and human tumour cell lines, even against
multidrug-resistance tumour cell lines that overexpress P-glyco-
protein (Watanabe et al, 1991). As a result, MX2 is considered a
candidate antitumour drug against multidrug resistant tumour
cells.
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sIn order to elucidate the cellular target of and resistance
mechanisms against MX2, we established an MX2-resistant human
leukaemia cell line (K562/MX2), which is eight-fold more resistant
to MX2 than the parental K562 cell line (K562/P). We observed
quantitative changes in Topo IIa in K562/MX2 cells when
compared with those in K562/P cells, whereas intracellular level
of MX2 was higher than in K562/P cells. Increased methylated CpG
islands in the Topo IIa gene were observed in K562/MX2 cells on
methylation-specific restriction enzyme analysis. To overcome
drug resistance to MX2 and etoposide, we investigated treatment
with 5-Aza-20-deoxycytidine (5AZ), which is a demethylating
agent, in K562/MX2 cells. 5-Aza-20-deoxycytidine treatment
increased Topo IIa mRNA expression in K562/MX2 cells, but not
in K562/P cells, and increased the cytotoxicity of MX2 and
etoposide. This suggests that Topo IIa might be the cellular target
of MX2.
MATERIALS AND METHODS
Drugs and chemicals
MX2 was prepared as described previously (Watanabe et al, 1991),
and its hydrochloride form was used in this study (Watanabe et al,
1988, 1991). Adriamycin, etoposide, VINCR istine (VCR) carbo-
platin and dimethyl sulphoxide (DMSO) were obtained from Wako
Pure Chemical Industries, Ltd (Osaka, Japan). Phosphate-buffered
saline without metal salt solution (PBS( )) was from Nissui
(Tokyo, Japan). RPMI 1640, Hanks’ balanced salt solution without
Ca
2þ or Mg
2þ (HBSS), foetal calf serum (FCS) and gentamicin
were purchased from Life Technologies, Inc. (Gaithersbug, MD,
USA).
Cell lines
K562/P, parental cell line of human myelogeneous leukaemia and
its ADM resistant subline K562/ADM were kindly provided by Dr
T Tsuruo (Cancer Chemotherapy Center, Japanese Foundation for
Cancer Research) and K562/P was obtained from American Type
Culture Collection (Manassas VA, USA). K562/ADM exhibited a
typical multidrug resistance phenotype. The growth medium for
K562/P and K562/ADM was RPMI-1640 medium supplemented
with 10% heat-inactivated foetal bovine serum and 100mgml
 1 of
kanamycin or gentamicin (R10). Cells were maintained at 371Ci na
humidified atmosphere containing 5% CO2. K562/ADM cells were
maintained in an ADM concentration of 0.3mgml
 1. An MX2-
resistant cell line was selected by stepwise and continuous
exposure to MX2 using the limiting dilution method. Prior to
use in each experiment, K562/MX2 was cultured without MX2 for 2
weeks. Cell sizes were determined using a Coulter channelizer
C-256 system (Nikkaki, Tokyo). All cell lines were free from
mycoplasma organisms, as confirmed by a MycoFluort Myco-
plasma detection kit (Molecular Probes, Eugene, OR, USA).
Cytotoxicity assay
Cytotoxicity was measured by trypan blue dye exclusion assay as
described previously (Ishiwaka et al, 1994). Briefly, 1 10
6 cells
were incubated with various concentrations of anticancer drugs,
including MX2, etoposide, ADM and VCR, for 72h and viable cells
were counted after trypan blue staining.
Assays for cellular uptake and efflux of MX2 and ADM
Intracellular uptake and efflux of MX2 and ADM were determined
by the method by Horichi et al (1990). To study uptake, each
1 10
6 K562/P or K562/MX2 cells were incubated with 0.25mmol
of MX2 or ADM for 120min. For efflux assay, tumour cells were
further incubated in drug-free medium for 120min. At each time
point, 1 10
6 cells were removed and washed twice with 10ml of
ice-cold PBS( ) and the incorporated MX2 or ADM was extracted
with 100ml of DMSO, and cellular proteins were then precipitated
with the addition of 0.4ml of absolute methanol. The fluorescence
intensity of the extracts was determined with a fluorescence
spectrophotometer at excitation and emission wavelengths of 485
and 535nm.
P-glycoprotein expression in leukaemia cells by flow
cytomery
Cells in various conditions were incubated with PE-labelled anti-
human P-glycoprotein antibody (Immunotech, Marseille, France)
for 30min at room temperature, washed with PBS three times and
analysed by flow cytometry (Coulter, CA, USA).
Northern blot analysis and RT–PCR
RNA was extracted, electrophoresed, transferred and hybridised
with a human Topo IIa gene probe (generous gift of Dr L Liu,
Robert Wood Johnson Medical School, University of Medicine and
Dentistry of New Jersey, NJ, USA), Topo IIa cDNA fragment, which
was amplified from a single-stranded cDNA library using primer
set 50-GGAGAGCAGCAACAAAAACA-30 (3953–3972) and 50-
CTTGCTTGTGACTGCTTTCG-30 (4484–4503), b-actin probe (gen-
erous gift of Dr Eugenie S Kleinerman, University of Texas, MD
Anderson Cancer Center), or human glyceraldehyde 3-phosphate
dehydrogenase cDNA (Asano et al, 1996a). RT–PCR was
performed according to the manufacturer’s instructions (Takara,
Ootsu). The primers used were 50-CCGTGTACTCCAACGCTGC-30
and 50-CTGGACCGCTGACGCCGTGAC-30 for multidrug resistance
protein1 (MRP1), yielding a PCR product of 326bp (Roller et al,
1999) and 50-GTGGGGCGCCCCAGGCACA-30 and 50-CTCCTTA
ATGTCACGCACGATTTC-30 for b-actin, yielding a PCR product
548bp (Brenner et al, 1989).
Immunoblot analysis of Topo II
K562/P, K562/ADM and K562/MX2 cells were pelleted (900 g)
and washed twice with cold PBS( ). Cells were resuspended at a
density of 2 10
7cellsml
 1 in 50mM Tris HCl (pH 7.4), 2% SDS,
1% b-mercaptoethanol, 1mM PMSF, 10mgml
 1 aprotinin and
10mgml
 1 leupeptin. Subsequently, cells were incubated at 651C
for 5min and passed 15–20 times through a 25-gauge needle.
Proteins from whole-cell lysate were prepared for SDS–polyacry-
lamide gel electrophoresis by addition of an equal volume of SDS
sample buffer (4% SDS, 0.2 M DTT, 20% glycerol) and boiling for
5min. Samples were electrophoresed (1 10
5cellslane
 1)o n7 %
SDS–polyacrylamide gels and transferred onto nitrocellulose
membranes as described previously (Zwelling et al, 1989; Harris
and Hochhauser, 1992; Asano et al, 1996a; Zhang et al, 1999). Blots
were probed with human Topo I antibody (TopoGEN, Inc.,
Columbus, OH, USA) and monoclonal antibodies 8D2, which
recognise the Mr 170000 form of the Topo IIa enzyme (kindly
provided by Dr A Kikuchi, Laboratory of Medical Micology,
Research Institute of Disease Mechanism and Control, Nagoya
University School of Medicine, Nagoya). Topo proteins were
detected using the Amersham enhanced chemiluminescence
detection system according to the protocols of the manufacturer.
Autoradiograms were evaluated by densitometry in order to
quantify the Topo signals.
Topoisomerase decatenation assays
Crude nuclear extracts from K562/P, K562/ADM and K562/MX2
cells were prepared as described previously with some modifica-
tion (Zwelling et al, 1989; Harris and Hochhauser, 1992; Zhang
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set al, 1999). Briefly, cells in the exponential phase of growth were
washed three times with five volumes of PBS( ) containing 1mM
PMSF, 1mM benzamidine and 1mgml
 1 soybean trypsin inhibitor,
and were then centrifuged for 5min at 1000 g. Cells were
resuspended in four volumes of 5mM potassium phosphate (pH
7.0), 2mM MgCl2, 0.1mM EDTA, 1mM PMSF, 1mM benzamidine,
10mgml
 1 soybean trypsin inhibitor, 50mgml
 1 leupeptin and
10mM 2-mercaptoethanol, and were stirred slowly at 41C for
15min. Nuclei were prepared by lysing cells with 10–15 strokes
from a chilled Dounce homogenizer. The extent of cell lysis was
monitored by microscopy. Cell lysate was centrifuged for 10min at
1000 g. Nuclei were washed twice with five volumes of 1mM
potassium phosphate (pH 6.5), 5mM MgCl2,1 m M EGTA, 10%
glycerol, 100mM NaCl, 1mM PMSF, 1mM benzamidine, 10mgml
 1
soybean trypsin inhibitor, 50mgml
 1 leupeptin and 10mM 2-
mercaptoethanol by centrifuging at 1000 g for 5min. Washed
nuclei were resuspended in extraction buffer (5mM potassium
phosphate (pH 7.0), 2mM MgCl2, 0.1mM EDTA, 1mM PMSF, 1mM
benzamidine, 10mgml
 1 soybean trypsin inhibitor, 50mgml
 1
leupeptin, 10mM 2-mercaptoethanol and 10% glycerol). NaCl was
added slowly to a final concentration of 0.35 M and topoisomerase
was extracted for 60min at 41C with constant stirring. Extracts
were centrifuged at 25000 g for 15min, and the supernatants
were used as topoisomerase extracts. Protein concentration in the
final extracts was determined by the method of Bradford.
Topoisomerase I activity was measured by the relaxation of
supercoiled DNA using a Topoisomerase I Assay Kit from
TopoGEN, Inc. (Columbus, OH, USA). Topoisomerase II catalytic
activity was assayed by decatenation of kDNA into free mini circles
using a Topoisomerase II Assay Kit from TopoGEN, Inc.
Relaxation and decatenation were carried out using topoisomerase
extracts, which contained 2–256ng of total protein, from K562/P,
K562/ADM and K562/MX2 with the appropriate supplements.
Reaction products were analysed by agarose gel electrophoresis
according to the manufacturer’s instructions.
Methylation status analysis using methylation-specific
enzyme
In total, 1mg of control, K562/P and K562/MX2 DNA was digested
with 100U of MspI and HpaII (Takara Shuzo, Ohtsu, Japan) at
371C for 16h. To analyse the methylation status of the Topo IIa
promoter region, restriction-digested DNA was analysed by PCR in
a 25-ml reaction mixture containing 1mmoll
 1 of each sense and
antisense primer, and 1U of Taq DNA polymerase. PCR primers
were as follows: 50-AGGCAGATGCCAGAATCTGTT-30, corre-
sponding to  550 to  529, and 50-AGGGCTCACTTGTTTTCTC
GT-30, corresponding to  284 to  263 (restriction site  489); and
50-GCTCCCATTCCCCTCGCTAAC-30, corresponding to  457 to
 436, and 50-AGGGCTCACTTGTTTTCTCGT-30, corresponding to
þ26 to þ47 (restriction site:  152), based on the sequence by
Hochhauser et al (1992). PCR products were separated by
electrophoresis on 2% agarose gels.
5-Aza-20-deoxycytidine treatment
Approximately 1 10
8 cells from various cell lines were grown on
medium containing 2, or 10mM 5AZ for 3 days, and the medium
and drug were replaced every 24h.
RESULTS
Establishment of MX2 resistant cell line
K562/MX2 was developed by continuously exposing cells to
gradually increasing doses of MX2. K562/MX2 is a subculture
under continuous exposure to 0.1mM MX2. This resistant
phenotype was also stable after more than 6 months of growth
in drug-free medium. The doubling time of K562/MX2 (29h) was
slightly longer than that of the parent cell line K562/P (25h) and
that of the K562/ADM line (24h). The diameter of K562/MX2
(8.7mm) was similar to that of parent cell line (8.6mm). K562/MX2
cells were resistant to MX2 and ADM and also showed cross-
resistance to etoposide (Table 1).
Accumulation and efflux of MX2 and ADM in K562/P and
K562/MX2 cells
In order to determine whether the resistance of K562/MX2 cells
against MX2 and ADM was related to decreased intracellular drug
concentration, the accumulation and efflux of the drugs in K562/
MX2 were analysed. The uptake of MX2 in K562/P and K562/ADM
cells reached a plateau within 30min in the presence of 5mmol of
drug over period 120min, but K562/MX2 continuously showed
increased MX2 concentration over the 120-min period (Figure 1A).
The amount of MX2 quickly decreased in the K562/MX2 cell line
after removal of MX2 from the culture media, and there was no
difference in the concentration of MX2 between the three cell lines
after the 120-min efflux period (Figure 1B). The intracellular
concentration of ADM in K562/P and K562/MX2 continuously
increased over the 120-min period. On the other hand, intracellular
concentration of ADM in K562/ADM cells reached a plateau in
20min (Figure 1C). Efflux of ADM was similar between K562/P
and K562/MX2 cells, and was much slower than in K62/ADM cells
(Figure 1D). P-glycoprotein expression was not detected in K562/P
and K562/MX2 cells (data not shown). On the other hand, RNA
expression of MRP1 was slightly higher in K562/MX2 and K562/
ADM when compared with K562/P cells (data not shown).
Table 1 IC50 against MX2 and etoposide, adriamycin, and vincristine with or without indomethacin, 5-Aza-20-deoxycytidine (5AZ) treatment
MX2 (nM) Etoposide (nM) Adriamycin (nM) Vincristine (nM) Carboplatin (lM)
K562/P 30741 0 742 0 73 2.072.1 2075.1
K562/P with indomethacin 28779 751 8 73 1.872.0 ND
K562/P with 2mM 5AZ 28758 75N D N D N D
K562/P with 10mM 5AZ 29767 74 15.0711.0 1.872.9 2274.8
K562/MX2 200723* 94715* 150720* 2.371.8 1876.0
K562/MX2 with indomethacin 190750* 90725* 100725* 1.871.0 ND
K562/MX2 with 2mM 5AZ 50712
a 1075
a ND ND ND
K562/MX2 with 10mM 5AZ 4679
a 875
a 130710.7 2.071.0 20.574.8
K562/ADM 2879.3 8.273.0 250750* 20.278.1* 2176.8
K562/ADM with indomethacin ND ND 50750** 573** ND
K562/ADM with 10mM 5AZ 3078.8 9.372.5 100720.8
a 5.072.8
a 2075.0
ND¼not done. IC50 was calculated from cytotoxicity against various drugs. Data were average7s.d. from five independent experiments. *Po0.05, cytotoxicity in K562/P vs
K562/MX2, or K562/ADM cells. **Po0.05, cytotoxicity in K562 cells with vs without indomethacin treatment.
aCytotoxicity in K562 cells with vs without 5AZ treatment.
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sIncubation with 3mgml
 1 of indomethacin, an inhibitor of MRP1,
for 72h decreased MRP1 RNA expression in K562/MX2 and K562/
ADM cells to a similar level as that in K562/P (data not shown).
However, cytotoxicity of MX2 and etoposide in K562/MX2 cells
treated with indomethacin was comparable to that in K562/MX2
cells without indomethacin treatment (Table 1). These results
suggest that the resistance of K562/MX2 cells to etoposide and
MX2 is not associated with P-glycoprotein, and that MRP1
contributes little to MX2 and etoposide resistance.
Topo IIa expression of in K562/P, K562/MX2 and K562/
ADM cells
Topo IIa mRNA expression was significantly lower in K562/MX2
cells and slightly lower in K562/ADM cells when compared with
K562/P cells (Figure 2A).
Topo I and Topo II protein in K562/P, K562/MX2 and
K562/ADM cells
Immunoblot analysis of whole-cell lysates from K562/P, K562/MX2
and K562/ADM cells revealed identical Topo I expression levels in
all cell lines (data not shown). Immunoblot analysis of whole-cell
lysates from K562/P, K562/MX2 and K562/ADM cells confirmed
the specific 170-kDa band of Topo IIa in all cell lines, but K562/
MX2 and K562/ADM cells showed lower levels than K562/P cells
(Figure 2B).
Topoisomerase decatenating activity in K562/P, K562/MX2
and K562/ADM cells
In several mammalian cell lines selected for resistance to Topo II
inhibitors, alterations in cellular Topo II protein activity, content
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Figure 1 (A) Accumulation of MX2 in K562/P, K562/ADM and K562/MX cells. Intracellular accumulation of MX2 in K562/P, K562/ADM and K562/MX2
was measured according to Materials and Methods. Representative data from three independent experiments. Error bar showed s.d. (B) The efflux of MX2
in K562/P, K562/ADM and K562/MX2. The efflux of MX2 in K562/P, K562/ADM and K562/MX2 cells was measured according to Materials and Methods.
Representative data from three independent experiments. Error bar showed s.d. (C) The accumulation of ADM in K562/P, K562/ADM and K562/MX cells.
Intracellular accumulation of ADM in K562/P, K562/ADM and K562/MX2 was measured according to Materials and Methods. Representative data from
three independent experiments. Error bar showed s.d. (D) The efflux of ADM in K562/P, K562/ADM and K562/MX2. The efflux of ADM in K562/P, K562/
ADM and K562/MX2 cells was measured according to Materials and Methods. Representative data from three independent experiments. Error bar showed
s.d.
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sor affinity for drugs have been demonstrated (Zwelling et al, 1989;
Asano et al, 1996b,c; Scheltema et al, 1997; Zhang et al, 1999).
MX2 inhibits Topo II decatenating activity in vitro (Horichi et al,
1990). We thus investigated Topo I and Topo II catalytic activities
in nuclear extracts from K562/P, K562/MX2 and K562/ADR cells.
There were no differences among those cells in Topo I-mediated
relaxation activity in nuclear extracts from exponentially growing
cells (data not shown). On the other hand, Topo II activity in
nuclear proteins from K562/MX2 cells was about 16-fold lower
than that in comparable K562/P extracts (Figure 3). In K562/ADM
nuclear extracts, the catalytic activity of Topo II was only two-fold
lower than that in K562/P extracts (Figure 3).
Increased methylation of CpG in Topo IIa gene in K562/
MX2 cells based on methylation-specific enzyme analysis
Increased methylation of the CpG site was confirmed in K562/MX2
cells at the proximal promoter region (position:  152, Figure 4),
but not at the distal promoter region (position:  489, data not
shown) of the Topo IIa gene by methylation-specific enzyme
analysis. There were no mutations in the promoter region
(position  566 to þ22) of the human Topo IIa gene in K562/P
and K562/MX2 cells, as compared to the published sequence
(Hochhauser et al, 1992).
Topo IIa mRNA expression after 5AZ treatment in K562/P
and K562/MX2 cells
We then determined whether aberrant methylation might confer
decreased expression of the Topo IIa gene. 5-Aza-20-deoxycytidine
treatment was performed in K562/P and K562/MX2 cells. Increased
human Topo IIa mRNA expression was observed after treatment
with 2 or 10mM of 5AZ in K562/MX2 cells, but not in K562/P cells
(Figure 5). However, the intensity of Topo IIa mRNA in K562/MX2
cells remained lower than that in K562/P cells.
Decreased CpG methylation in Topo IIa in K562/MX2 cells
treated with 5AZ
In K562/MX2 cells treated with 5AZ, fewer methylated CpG sites
were observed on methylation-specific enzyme analysis (Figure 4).
Effect of 5AZ treatment on MX2 and etoposide cytotoxicity
in K562/P, K562/ADM and K562-MX2 cells
Increased cytotoxicity of MX2 and etoposide was observed in 5AZ-
treated K562/MX2 cells, but was not observed in 5AZ-treated
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Figure 2 (A) Expression of topoisomerase IIa mRNA in K562/P, K562/
MX2 and K562/ADM. Human topoisomerase IIa mRNA expression in
K562/P, K562/ADM and K562/MX2 was measured. Significantly decreased
expression of human topoisomerase IIa was observed in K562/MX2 cells.
In K562/ADM cells, slightly decreased expression of human topoisomerase
IIa was observed. Representative data from three independent experi-
ments. (B) Expression of topoisomerase IIa protein in K562/P, K562/MX2
and K562/ADM: Decreased expression of human topoisomerase IIa
protein in K562/MX2 was observed. Representative data from three
independent experiments.
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Figure 3 Topo II-mediated decantenation activity in nuclear extracts
from in K562/P, K562/MX2 and K562/ADM cells. Decreased decantenation
activity in K562/MX2was observed compared to in K562/P and K562/ADM
cells. Representative data from three independent experiments.
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sK562/P and K562/ADM cells (Table 1). Also carboplatin, which act
as an independent mechanism of Topo II, showed no enhanced
sensitivity with 5AZ treatment. In 5AZ-treated K562/ADM cells,
decreased resistance against ADM and VCR were observed as same
as previous literature (Efferth et al, 2001). Under 10mM of 5AZ
treatment for 1 week showed no cytotoxic effect against K562/P,
K562/ADM and K562/MX2 cells (data not shown).
DISCUSSION
Drug resistance is a major obstacle in cancer therapy. The
molecular target of drug action for amino acridines, anthracyclines
and epipodophyllotoxins has been reported to be topoisomerase
(Zwelling et al, 1989). Multiple resistance to Topo II poisons exist
in two major forms: one is attributable to an efflux pump in the cell
membrane that lowers the steady-state concentration of the drug at
the target site, and in the other form, the activity and sensitivity of
the target enzyme Topo II itself are decreased by downregulation
or mutation (Kellner et al, 2002).
KRN 8602 (MX2) is a novel morpholino anthracycline derivative
with the chemical structure 30-deamino-30-morpholino-13-deoxo-
10-hydroxycarminomycin hydrochloride, and has been demon-
strated to have cytotoxic effects against tumour cells as a Topo II
inhibitor (Watanabe et al, 1988). MX2 is highly lipophilic and has
been shown to rapidly diffuse through the cell membrane and
reach high intracellular concentrations regardless of P-glycopro-
tein expression levels (Watanabe et al, 1988). To elucidate the
cellular target of and resistance mechanisms against MX2, we
established an MX2-resistant human leukaemia cell line (K562/
MX2) that is more resistant to MX2 and etoposide than the
parental K562 cell line (K562/P), and we investigated the
mechanisms Topo II-targeting drugs in K562/MX2 cells.
We found that the accumulation and efflux of MX2 were
marginally different in the MX2-resistant cell line. P-glycoprotein
expression was similar in both K562/P and K562/MX2 cells. The
role of the MRP1 gene is possibly marginal because indomethacin,
an inhibitor of the MRP1 gene, did not alter the sensitivity to MX2
and etoposide in K562/MX2 cells. The resistance of numerous cell
lines and clinical samples to doxorubicin has been found to be
MDR1 or MRP1 mediated (Legrand et al, 1998, 1999). Based on the
present results, it is reasonable to conclude that the resistance of
K562/MX2 to etoposide, and MX2 does not involve MDR1 or MRP1.
On the other hand, we observed decreased expression of the
Topo IIa gene in K562/MX2 cells, but found no change in Topo I
gene expression. From a clinical perspective, mutations in Topo II
do not seem to have a major role in resistance (Kudo et al, 1996;
Kellner et al, 2002). In addition to these findings, forced induction
of Topo IIa gene expression in etoposide-resistant cell lines using a
dexamethasone inducible vector or a recombinant adenovirus
vector containing normal human or drosophila Topo IIa overcame
etoposide resistance (Asano et al, 1996a–c; Zhang et al, 1999).
Decreased expression of human Topo IIa might therefore be a
major factor in drug resistance to etoposide and other drugs.
When analyzing the mechanisms of decreased Topo IIa expres-
sion, increased methylation of CpG islands in the Topo IIa gene
were observed in K562/MX2 cells by methylation-specific restric-
tion enzyme analysis. Aberrant methylation of several genes has
been frequently reported in cancer development (Roman-Gomez
et al, 2002). With regard to drug resistance, the several genes in
which methylation was found to be related to drug resistance, such
as MDR1 (Nakayama et al, 1998), caspase-8 (Worm and Guldberg,
2002; Paz et al, 2003), O(6)-methylguanine-DNA methyltransferase
gene (Christmann et al, 2001), glutathione-S transferase P1
(Esteller et al, 1998) and hMLH1 gene (Plumb et al, 2000). The
present results might be suggestive of a novel methylation-related
mechanism of drug resistance. Interestingly, this resistance seems
to have occurred via increased methylation of the target gene as
well as decreased expression of a resistance-related gene, which is
in complete contrast to resistance mechanisms involving the
MDR1 gene.
In order to overcome resistance to MX2, we investigated
treatment with 5AZ, which is a demethylating agent, in K562/
MX2 cells. 5-Aza-20-deoxycytidine treatment increased Topo IIa
mRNA expression in K562/MX2 cells, but not in K562/P cells, and
increased cytotoxicity to MX2 and etoposide. CpG methylation was
decreased in K562/MX2 cells after 5AZ treatment. Furthermore,
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Figure 4 Methylation status of promoter region in K562/P and K562/
MX2 cells by methylation-specific restriction enzyme analysis with or
without 5-Aza-20-deoxycytidine treatment. Aberrant methylation of CpG
site was observed in K562/MX2 cells at the proximal promoter region
(position:  152) by methylation-specific enzyme analysis (arrow head).
PCR products in K562/P cells showed arrow. Representative data from five
independent experiments.
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Figure 5 Topoisomerase IIa mRNA expression with 5-Aza-20-deox-
ycytidine treatment in K562/P and K562/MX2 cells. Increased expression of
topoisomerase IIa RNA in K562/MX2 treated with 5-Aza-20-deoxycytidine
was observed. However, increased expression in 5AZ treated K562/MX2
cells was not fully restored compared inK562/P cells. Representative data
from six independent experiments.
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cytotoxicity to MX2 and etoposide in K562/MX cells. This suggests
that Topo IIa might be the cellular target of MX2. These findings
were also observed in an etoposide-resistant breast cancer cell line
(Asano, unpublished results). 5-Aza-20-deoxycytidine also in-
creased expression of many other genes in cancer cells, such as
caspase-8 (Worm and Guldberg, 2002; Paz et al, 2003) and hMLH
gene (Plumb et al, 2000). Such altered expression of genes by 5AZ
treatment might contribute to restore the drug resistance in
resistant cell lines. 5-Aza-20-deoxycytidine is now used to treat
myelodysplastic syndrome in clinical settings (Kornblith et al,
2002; Silverman et al, 2002). Based on the present results, we
believe that 5AZ also might be applicable to patients exhibiting
drug resistance, particularly to MX2 and etoposide.
In conclusion, the present MX2-resistant phenotype exhibits
decreased expression of the topoisomerase IIa gene together with
increased methylation of this gene.
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